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ABSTRACT
Objective: This study aimed at determination of safety and efficacy of combination therapy of dapagliflozin and metformin in the treatment of Type 
2 diabetes mellitus.
Methods: A total of 50 patients were enrolled in the study depending on demographic parameters and clinical data of the patients. The primary 
efficacy criterion was the change in glycated hemoglobin (HbA1c) after a minimum of 12 weeks of treatment. Secondary efficacy parameters were 
HbA1c value after 12 weeks, fasting and 1 hrs postprandial glucose, serum insulin and triglyceride levels, after a standardized meal, all after 12 weeks 
of treatment. Safety and tolerability were evaluated by the incidence of adverse events reported by patients. Patient visits to the clinical center were 
scheduled at screening, start of the run-in period.
Results: Reductions in levels of postprandial plasma glucose were observed in all the active treatment groups. The reductions in patients receiving 
metformin plus dapagliflozin combination therapy were significantly greater (p<0.0001). It was clear that lower postprandial plasma insulin levels 
despite higher postprandial plasma glucose levels suggest decreased β-cell function. Changes in fasting serum insulin observed from baseline to the 
end of treatment did not differ significantly between metformin plus dapagliflozin combination therapy and metformin monotherapy and showed no 
consistent trend.
Conclusion: The results from the study suggest that the combination of the drugs was effective in controlling glycemic levels and also were safe. No 
serious adverse drug reactions were reported by the patients when used daily once for 6 months.
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INTRODUCTION
Diabetes mellitus is a major global health problem and an increasing 
cause of morbidity and mortality [1]. The term diabetes mellitus 
describes a metabolic disorder of multiple etiology, characterized 
by chronic hyperglycemia with disturbances of carbohydrate, fat 
and protein metabolism resulting from defects in insulin secretion, 
insulin action or both [2]. The diseased state underlying the diagnosis 
of diabetes mellitus are classified into four categories namely 
Type 1 - insulin-dependent diabetes mellitus, Type 2 - noninsulin-
dependent diabetes mellitus, and Type 3 - gestational diabetes mellitus, 
and others. According to recent estimates, approximately 285 million 
people worldwide (6.6%) in the 20-79 year age group have diabetes 
and by 2030, 438 million people (7.8%) of the adult population, is 
expected to have diabetes [3].
The World Health Organization estimates that worldwide, there are 
currently 220 million people living with diabetes [4]. In 2010, there 
were 45.2 million cases of Type 2 diabetes mellitus (T2DM) in India. Of 
these, 14.7 million and 30.5 million were found in rural and urban areas, 
respectively. By the end of 2011 and 2020, data monitoring estimates 
that the total prevalent cases of Type 2 diabetes increased to 47.2 and 
69.7 million, respectively [5]. The major cities of India (New Delhi, 
Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, and Ahmadabad) 
have got an estimated 7.3 million prevalent cases of Type 2 diabetes 
in 2010. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) 
inhibitor which prevents glucose reabsorption in the kidney [6]. It 
is indicated in the management of T2DM, and functions to improve 
glycemic control in adults when combined with diet and exercise. 
Metformin lowers blood glucose levels by various mechanisms such 
as suppressing hepatic gluconeogenesis and glucose output from 
liver, enhancing insulin mediated glucose disposal in muscle and fat, 
retarding intestinal absorption of glucose, other hexoses, amino acids 
and vitamin-B12 and interfering with mitochondrial respiratory 
chain [7]. This study was conducted to determine the safety and efficacy 
of combination of these two drugs in patients with T2DM.
MATERIALS AND METHODS
Materials
Combination of dapagliflozin 5 mg plus metformin 500 mg was used in 
the study The patients which were included in the study were male or 
female, aged between 30 and 75, who had been diagnosed with T2DM for 
at least 1 year and whose diabetes was inadequately controlled by diet 
and metformin taken at a stable dose for at least 3 months. Furthermore, 
the patients were required to have glycated hemoglobin (HbA1c), ≥7.5% 
and ≤10.5% at baseline, body mass index between 23 and 40 kg/m2, and 
stable body weight (5%) over the 3 months preceding enrolment. Subjects 
with serious medical conditions including hepatic or renal dysfunction, 
decompensate heart failure, serious hemopoietic disorders, or any 
gastrointestinal disorders were excluded from the study [8]. Patients 
who used either any oral antidiabetics other than metformin within the 
30 days before enrolment or diuretics and glucocorticoids unless at a 
constant dose in the 3 months before enrolment were not included.
Methodology
The study was conducted in Prime Hospital, Hyderabad. An ethical 
clearance, ECR/381/Inst/AP/2013 was obtained from the hospital 
and all patients were requested to fill the informed consent form. 
Around 50 patients, who satisfied the eligibility criteria, were included 
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during the study period. These patients were evaluated according to 
the treatment protocol. Data collection form was designed to collect 
data of the patients including personal details (name, age, sex height, 
weight, address, marital status, and occupation) family history, and past 
medical history, complications, and life style modification [9].
Primarily a detailed history of the patients enrolled was ascertained 
and entered in the case report form. Furthermore, a detailed previous 
history of drugs such as antibiotics and any history of previous 
hospitalization, associated illness and habits and diet any significant 
family history was also recorded. Patient visits to the clinical center 
were scheduled at screening, start of the run-in period. HbA1c was 
measured at screening, baseline, week 12, and thereafter at each visit 
if the preceding visit’s value had been >11%. HbA1c was measured 
by high performance liquid chromatography, serum glucose by the 
glucose-oxidase method [10], serum insulin by double antibody 
radioimmunoassay. Fasting blood glucose and fasting urine glucose was 
measured at screening and week 12.
Statistical analysis
Statistical analysis was done using GraphPad Prism software to 
calculate the probability of significance.
RESULTS
A total of 50 patients were enrolled in the study. Considering the first 
parameter of gender there were 30 males and 20 females enrolled in 
the study group (Table 1). Average baseline HbA1c (%) in reference 
group was 8.2 in test group (Graph 1). The change in the HbA1c (%) 
of the patients who responded clinically is presented in the Graph 
2. Table 2 and Graph 2 present the overall efficacy assessment after 
the drug therapy for 6 months. The change in the HbA1c (%) was 
considered to measure the efficacy in both groups. The test group and 
reference group both showed clinical response. There was significant 
change in HbA1c (%) after the drug treatment. The adverse drug 
reactions reported by the subjects of both groups were recorded 
(Table 3). Flatulence was reported by two subjects in reference and 
one in test. Diarrhea was reported by five in reference and two in 
the test group. Nausea was reported by one in reference and two in 
test group, abdominal cramps were not reported in the reference 
group but one subject experienced the condition. Constipation 
was reported by seven subjects in both reference and test groups. 
Back pain was reported by one in reference and two in test group 
presented in Graph 3. Hypotension was reported by five patients, 
lowering of both systolic and diastolic BP in patients. It was clear that 
lower postprandial plasma insulin levels despite higher postprandial 
plasma glucose levels suggest decreased β-cell function. Changes in 
fasting serum insulin observed from baseline to the end of treatment 
did not differ significantly between metformin plus dapagliflozin 
combination therapy and metformin monotherapy and showed no 
consistent trend.
DISCUSSION
Dapagliflozin, one of group SGLT2 inhibitors, is effective as 
monotherapy and in combination with other antihyperglycemic 
agents in reducing HbA1C in T2DM [11]. This study demonstrates that 
dapagliflozin provides a greater clinical response or effect of strong 
glycemic control, as indicated by the marked reductions in HbA1c and 
plasma glucose levels in middle-aged patients in whom Type 2 diabetes 
is insufficiently controlled by dietary management. The reductions 
in fasting and postprandial plasma glucose as well as in HbA1c in 
response to combination of dapagliflozin plus metformin therapy. 
The Test drug acts synergistically to confer this additional glycemic 
control, especially on postprandial plasma glucose peaks, and may 
thereby help to reduce the risk of microvascular and macrovascular 
diabetic complications. From our study, the 3-6 months treatment 
showed greater efficacy and safety for short-term study in the finished 
population. The hypotension observed in the study might be due to 
combination therapy.
Table 1: Baseline demographic parameters
Parameters Test group n=50
Age 57.3 ± 9.0




Duration of disease 7.2
HbA1c (%) 8.2
BMI: Body mass index, HbA1c: Glycated hemoglobin
Table 2: Change in HbA1c (%) EOT





EOT: End of treatment, HbA1c: Glycated hemoglobin
Graph 1: Baseline demographic characters
Graph 2: Change in glycated hemoglobin (%) end of treatment
Graph 3: Adverse drug reactions reported
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T2DM is a prevalent, progressive disease with a need for innovative 
therapeutic agents to continue to advance disease management. The 
decrease in insulin resistance has been shown to have effects on lipid 
profiles as patients who develop T2DM [12]. Besides β-cell failure, the 
major pathophysiological event contributing to the development of 
T2DM is the resistance of target tissues to insulin [13]. Dapagliflozin 
is the second agent in a new class of oral antihyperglycemic drugs: 
SGLT2 inhibitors. SGLT2 is responsible for the majority of renal glucose 
reuptake; inhibition of the cotransporter allows for increased renal 
glucose excretion that consequently leads to reduced plasma glucose 
levels [14]. Because this mechanism does not require the action of 
insulin, dapagliflozin rarely causes hypoglycemia and is effective in 
patients both early and late in the course of their disease. Studies of 
dapagliflozin have demonstrated efficacy both as monotherapy and 
in combination with oral antihyperglycemic agents and insulin. The 
patients responded to the combination of drugs dapagliflozin a new 
SGLT2 drug has shown superior clinical response in reducing the blood 
glucose level, the clinical response was significantly more in the test 
group. The results show that the drug is safe when studied for the 
period of 6 months, further studied must be done to check the safety 
of the drugs in long-term use. The combination of SGLT2 drug and 
metformin have shown significant efficacy in patients with T2DM for 
6 months. The study suggests that the combination of these drugs have 
shown minimal adverse drug reactions when used for the periods of 
6 months.
CONCLUSION
In conclusion, the results from the study suggest that the combination 
of the drugs were effective in controlling glycemic levels and also safe, 
no patient had reported serious adverse drug reactions when used 
daily once for 6 months. The study also suggests that the patients with 
hypotension may have risk for severe hypotension. The adverse drug 
reactions were studied for short-term duration. No patient have been 
reported any serious adverse drug reactions. The study suggests that 
the drug administration for 6 months is safe and effective. Further 
studies should be done on the combination of drugs for long term.
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Table 3: Adverse drug reactions
Adverse drug reactions Test group (n-20)
Flatulence 1
Diarrhea 2
Nausea 2
Abdominal cramps 1
Constipation 7
Back pain 2
Hypotension 5
Hypoglycemia 20
Renal impairment 15
